Cited by 1,248Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenomics and Rare Diseases

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The IARC TP53 database: New online mutation analysis and recommendations to users

Open access

Olivier, Magali, Eeles, Ros, Hollstein, Monica, Khan, Mohammed A., Harris, Curtis C., Hainaut, Pierre·2002·Human Mutation

DOI 10.1002/humu.10081

Open this paper in CoChat — free account Open PDF

Abstract

Mutations in the tumor suppressor gene TP53 are frequent in most human cancers. Comparison of the mutation patterns in different cancers may reveal clues on the natural history of the disease. Over the past 10 years, several databases of TP53 mutations have been developed. The most extensive of these databases is maintained and developed at the International Agency for Research on Cancer. The database compiles all mutations (somatic and inherited), as well as polymorphisms, that have been reported in the published literature since 1989. The IARC TP53 mutation dataset is the largest dataset available on the variations of any human gene. The database is available at www.iarc.fr/P53/. In this paper, we describe recent developments of the database. These developments include restructuring of the database, which is now patient-centered, with more detailed annotations on the patient (carcinogen exposure, virus infection, genetic background). In addition, a new on-line application to retrieve somatic mutation data and analyze mutation patterns is now available. We also discuss limitations on the use of the database and provide recommendations to users.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/humu.10081

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53 and Human Cancer: The First Ten Thousand Mutations
Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 999
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M. L., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 899
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241
p53 gene mutation: software and database
Béroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 185
p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
Vahteristo, P., Tamminen, A., Karvinen, P., Eerola, H., Eklund, C., Aaltonen, L. A., BLOMQVIST, C. P., Aittomäki, K., & Nevanlinna, H. A. (2001) · PubMed · Cited by 180
p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer
Hussain, S. P., & Harris, C. C. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s1383-5742(99)00028-9 · Cited by 164
p53 and the Li-Fraumeni syndrome
Malkin, D. M. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90233-c · Cited by 153
p53 gene mutation: software and database
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 149

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 3

Greenblatt, 1994, Cancer Res, 54, 4855
Hollstein, 1994, Nucleic Acids Res, 22, 3551
Vahteristo, 2001, Cancer Res, 61, 5718

Sorted by citations

Items 101–200 of 1,000

A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans
Bond, G. L., & Levine, A. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210199 · Cited by 186
(−)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-XL-mediated apoptosis resistance
Oliver, C. L., Miranda, M. B., Shangary, S. K., Land, S. R., Wang, S., & Johnson, D. E. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.23.4.1 · Cited by 182
Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium
Goebell, P. J., & Knowles, M. A. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.04.003 · Cited by 181
Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations
Joerger, A. C., Ang, H. C., Veprintsev, D. B., Blair, C. M., & Fersht, A. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500179200 · Cited by 181
Making waves in cancer research: new models in the zebrafish.
Berghmans, S., Jette, C. A., Langenau, D. M., Hsu, K., Stewart, R., Look, T., & Kanki, J. P. (2005) · BioTechniques · doi:10.2144/05392rv02 · Cited by 170
Human papillomavirus and oropharynx cancer: Biology, detection and clinical implications
Allen, C. T., Lewis, J. S., El‐Mofty, S. K., Haughey, B. H., & Nussenbaum, B. A. (2010) · The Laryngoscope · doi:10.1002/lary.20936 · Cited by 175
Solution structure of p53 core domain: Structural basis for its instability
Cañadillas, J. M. P., Tidow, H., Freund, S. M. V., Rutherford, T. J., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510941103 · Cited by 174
Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer
Arlt, V. M., Stiborová, M., Brocke, J. V., Simões, M. L., Lord, G. M., Nortier, J., Hollstein, M., Phillips, D. H., & Schmeiser, H. H. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm082 · Cited by 173
Zebrafish Models for Cancer
Liu, S., & Leach, S. D. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130330 · Cited by 180
High-Resolution Single Nucleotide Polymorphism Array Analysis of Epithelial Ovarian Cancer Reveals Numerous Microdeletions and Amplifications
Gorringe, K. L., Jacobs, S., Thompson, E. R., Sridhar, A., Qiu, W., Choong, D. Y. H., & Campbell, I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0502 · Cited by 171
Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications
Rudin, C. M., Ávila-Tang, É., Harris, C. C., Herman, J. G., Hirsch, F. R., Pao, W. J., Schwartz, A. G., Vähäkangas, K., & Samet, J. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0377 · Cited by 175
MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53
Enge, M., Bao, W., Hedström, E., Jackson, S. P., Moumen, A., & Selivanova, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.019 · Cited by 172
High frequency of de novo mutations in Li–Fraumeni syndrome
Gonzalez, K. D., Buzin, C. H., Noltner, K., Gu, D., Li, W., Malkin, D. M., & Sommer, S. S. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.058958 · Cited by 170
p53 and disease: when the guardian angel fails
Royds, J. A., & Iacopetta, B. M. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401913 · Cited by 168
TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 184
TP53 and KRAS2 Mutations in Plasma DNA of Healthy Subjects and Subsequent Cancer Occurrence: A Prospective Study
Gormally, E., Vineis, P., Matullo, G., Veglia, F., Caboux, É., Roux, E. L., Peluso, M. E. M., GARTE, S. J., Guarrera, S., Munnia, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4556 · Cited by 168
Clinical and molecular features of treatment‐related neuroendocrine prostate cancer
Akamatsu, S., Inoue, T., Ogawa, O., & Gleave, M. E. (2018) · International Journal of Urology · doi:10.1111/iju.13526 · Cited by 162
The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute
de Andrade, K. C., Lee, E. E., Tookmanian, E. M., Kesserwan, C. A., Manfredi, J. J., Hatton, J. N., Loukissas, J. K., Zavadil, J., Zhou, L. J., Olivier, M., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-00976-3 · Cited by 171
Molecular knots in biology and chemistry
Lim, N. C. H., & Jackson, S. (2015) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/27/35/354101 · Cited by 162
The role of p53 in treatment responses of lung cancer
Viktorsson, K., Petris, L. D., & Lewensohn, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.192 · Cited by 161
Broad spectrum and potent antitumor activities of YM155, a novel small‐molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models
Nakahara, T., Kita, A., Yamanaka, K., Mori, M., Amino, N., Takeuchi, M., Tominaga, F., Kinoyama, I., Matsuhisa, A., Kudou, M., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01834.x · Cited by 160
Transcription, apoptosis and p53: catch-22
Schüler, M., & Green, D. R. (2005) · Trends in Genetics · doi:10.1016/j.tig.2005.01.001 · Cited by 161
Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
Maerken, T. V., Speleman, F., Vermeulen, J., Lambertz, I., Clercq, S. D., Smet, E. D., Yigit, N., Coppens, V., Philippé, J., Paepe, A. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0792 · Cited by 154
The UMD-p53 database: New mutations and analysis tools
Béroud, C., & Soussi, T. (2003) · Human Mutation · doi:10.1002/humu.10187 · Cited by 155
Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance
Taneja, P., Maglic, D., Kai, F., Zhu, S., Kendig, R. D., Elizabeth, A., & Inoue, K. (2010) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s4773 · Cited by 160
Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
Xu, J., Liu, Y., Li, Y., Wang, H., Stewart, S., der Jeught, K. V., Agarwal, P., Zhang, Y., Liu, S., Zhao, G., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0381-6 · Cited by 153
Sub-attomole oligonucleotide and p53 cDNA determinations via a high-resolution surface plasmon resonance combined with oligonucleotide-capped gold nanoparticle signal amplification
Yao, X., Li, X., Toledo, F., Zurita‐Lopez, C. I., Gutova, M., Momand, J. A., & Zhou, F. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.04.011 · Cited by 153
GermlineTP53Mutations and the Changing Landscape of Li-Fraumeni Syndrome
Kamihara, J., Rana, H. Q., & Garber, J. E. (2014) · Human Mutation · doi:10.1002/humu.22559 · Cited by 153
Childhood solid tumours: a developmental disorder
Scotting, P. J., Walker, D. A., & Perilongo, G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1633 · Cited by 152
Crystal Structure of the p53 Core Domain Bound to a Full Consensus Site as a Self-Assembled Tetramer
Chen, Y., Dey, R., & Chen, L. (2010) · Structure · doi:10.1016/j.str.2009.11.011 · Cited by 156
A pivotal role for p53: balancing aerobic respiration and glycolysis
Ma, W., Sung, H. J., Park, J., Matoba, S., & Hwang, P. M. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9083-0 · Cited by 153
Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis
Hernández‐Vargas, H., Palacios, J., & Moreno‐Bueno, G. (2006) · Oncogene · doi:10.1038/sj.onc.1210102 · Cited by 150
Role of Environmental Toxins in Endemic (Balkan) Nephropathy
Grollman, A. P., & Jelaković, B. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050537 · Cited by 150
3DM: Systematic analysis of heterogeneous superfamily data to discover protein functionalities
Kuipers, R. K. P., Joosten, H., van Berkel, W. J. H., Leferink, N. G. H., Rooijen, E., Ittmann, E., van Zimmeren, F., Jochens, H., Bornscheuer, U. T., Vriend, G., et al. (2010) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22725 · Cited by 149
A Comparison of Multiscale Methods for the Analysis of Molecular Dynamics Simulations
Benson, N. C., & Daggett, V. (2012) · The Journal of Physical Chemistry B · doi:10.1021/jp302103t · Cited by 153
Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study
Lulla, R. R., Goldman, S., Yamada, T., Beattie, C. W., Bressler, L. R., Pacini, M., Pollack, I. F., Fisher, P. G., Packer, R. J., Dunkel, I. J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now047 · Cited by 148
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer
Naume, B., Zhao, X., Synnestvedt, M., Borgen, E., Russnes, H. G., Lingjærde, O. C., Strømberg, M., Wiedswang, G., Kvalheim, G., Kåresen, R., et al. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.03.004 · Cited by 143
Predicting changes in protein thermodynamic stability upon point mutation with deep 3D convolutional neural networks
Li, B., Yang, Y., Capra, J. A., & Gerstein, M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008291 · Cited by 142
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
Wiman, K. G. (2010) · Oncogene · doi:10.1038/onc.2010.188 · Cited by 148
p53 Isoforms and Their Implications in Cancer
Vieler, M., & Sanyal, S. (2018) · Cancers · doi:10.3390/cancers10090288 · Cited by 153
Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers
Dearth, L. R., Hua, Q., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl132 · Cited by 139
Genetic Alterations in Esophageal Cancer
Kuwano, H., Kato, H., Miyazaki, T., Fukuchi, M., Masuda, N., Nakajima, M., Fukai, Y., Sohda, M., Kimura, H., & Faried, A. (2004) · Surgery Today · doi:10.1007/s00595-004-2885-3 · Cited by 136
Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity
Resnick, M. A., & Inga, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1633803100 · Cited by 149
Discriminating functional and non‐functional p53 in human tumours by p53 and MDM2 immunohistochemistry
Nenutil, R., Šmardová, J., Pavlová, Š., Hanzelková, Z., Müller, P., Fabián, P., Hrstka, R., Janotova, P., Radina, M., Lane, D. P., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1838 · Cited by 135
Mutator pathways unleashed by epigenetic silencing in human cancer
Jacinto, F. V., & Esteller, M. (2007) · Mutagenesis · doi:10.1093/mutage/gem009 · Cited by 135
Strategies for therapeutic targeting of the p53 pathway in cancer
Wiman, K. G. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401921 · Cited by 135
Determination of TP53 Mutation Is More Relevant Than Microsatellite Instability Status for the Prediction of Disease-Free Survival in Adjuvant-Treated Stage III Colon Cancer Patients
Westra, J. L., Schaapveld, M., Hollema, H., de Boer, J. P., Kraak, M. M. J., de Jong, D., ter Elst, A., Mulder, N. H., Buys, C. H. C. M., Hofstra, R. M. W., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.096 · Cited by 137
DNA Damage-Induced Phosphorylation of MdmX at Serine 367 Activates p53 by Targeting MdmX for Mdm2-Dependent Degradation
Okamoto, K., Kashima, K., Pereg, Y., Ishida, M., Yamazaki, S., Nota, A., Teunisse, A., Migliorini, D., Kitabayashi, I., Marine, J.-C., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9608-9620.2005 · Cited by 129
Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil
Palmero, E. I., Schüler‐Faccini, L., Caleffi, M. M., Achatz, M. I., Olivier, M., Martel‐Planche, G., Marcel, V., de Aguiar, E. S., Giacomazzi, J., Ewald, I. P., et al. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.10.044 · Cited by 132
Aristolochic acid‐induced upper tract urothelial carcinoma in Taiwan: Clinical characteristics and outcomes
Chen, C., Dickman, K. G., Huang, C., Moriya, M., Shun, C., Tai, H., Huang, K., Wang, S., Lee, Y., Grollman, A. P., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28013 · Cited by 131
3-Nitrobenzanthrone, a potential human cancer hazard in diesel exhaust and urban air pollution: a review of the evidence
Arlt, V. M. (2005) · Mutagenesis · doi:10.1093/mutage/gei057 · Cited by 130
The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival
O’Shea, D., Ó’Riain, C., Taylor, C., Waters, R., Carlotti, E., MacDougall, F., Gribben, J. G., Rosenwald, A., Ott, G., Rimsza, L. M., et al. (2008) · Blood · doi:10.1182/blood-2008-05-154013 · Cited by 130
HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53Preprint
Sasaki, T., Gan, E. C., Wakeham, A. C., Kornbluth, S. A., Mak, T. W., & Okada, H. (2007) · Genes & Development · doi:10.1101/gad.1534107 · Cited by 130
Control of cell migration: a tumour suppressor function for p53?
Roger, L., Gadéa, G., & Roux, P. (2006) · Biology of the Cell · doi:10.1042/bc20050058 · Cited by 132
p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components
Lien, H., Lin, C., Mao, T., Kuo, S., Hsiao, C.-H., & Huang, C. (2004) · The Journal of Pathology · doi:10.1002/path.1624 · Cited by 123
Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population
Ørsted, D. D., Bojesen, S. E., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062476 · Cited by 122
Li‐Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition
Valdez, J. M., Nichols, K. E., & Kesserwan, C. A. (2016) · British Journal of Haematology · doi:10.1111/bjh.14461 · Cited by 124
Structural Biology of the Tumor Suppressor p53 and Cancer‐Associated Mutants
Joerger, A. C., & Fersht, A. R. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97001-8 · Cited by 131
The Codon 47 Polymorphism in p53 Is Functionally Significant
Li, X., Dumont, P., Pietra, A. D., Shetler, C. M., & Murphy, M. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414637200 · Cited by 118
Molecular Analysis to Detect Pancreatic Ductal Adenocarcinoma in High-Risk Groups
Yan, L., McFaul, C., Howes, N., Leslie, J., Lancaster, G., Wong, T., Threadgold, J., Evans, J. E., Gilmore, I. T., Smart, H. L., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.006 · Cited by 117
Mutant p53 targeting by the low molecular weight compound STIMA‐1
Zache, N., Lambert, J. M. R., Rökaeus, N., Shen, J., Hainaut, P. L., Bergman, J., Wiman, K. G., & Bykov, V. J. N. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.02.004 · Cited by 120
Role of the nucleus in apoptosis: signaling and execution
Prokhorova, E. A., Zamaraev, A. V., Kopeina, G. S., Zhivotovsky, B., & Lavrik, I. N. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2031-y · Cited by 116
New Waves of Discovery: Modeling Cancer in Zebrafish
Goessling, W., North, T. E., & Zon, L. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9821 · Cited by 115
MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling
Cha, Y. H., Kim, N. H., Park, C., Lee, I., Kim, H. S., & Yook, J. I. (2012) · Cell Cycle · doi:10.4161/cc.19618 · Cited by 115
p53—A Natural Cancer Killer: Structural Insights and Therapeutic Concepts
Römer, L., Klein, C., Dehner, A., Kessler, H., & Büchner, J. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600611 · Cited by 117
p53 ancestry: gazing through an evolutionary lens
Lu, W.-J., Amatruda, J. F., & Abrams, J. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2732 · Cited by 112
Molecular pathogenesis of bladder cancer
Knowles, M. A. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0812-0 · Cited by 117
Regulation of p53 Nuclear Export through Sequential Changes in Conformation and Ubiquitination
Nie, L., Sasaki, M. M., & Maki, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610515200 · Cited by 114
Importance of TP53 codon 72 and intron 3 duplication 16bppolymorphisms in prediction of susceptibility on breast cancer
Costa, S., Pinto, D., Pereira, D., Rodrigues, H., Cameselle‐Teijeiro, J., Medeiros, R., & Schmitt, F. C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-32 · Cited by 114
Group variable selection via a hierarchical lasso and its oracle property
Zhou, N., & Zhu, J. (2010) · Statistics and Its Interface · doi:10.4310/sii.2010.v3.n4.a13 · Cited by 119
p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3
Chappell, W. H., Lehmann, B. D., Terrian, D. M., Abrams, S. L., Steelman, L. S., & McCubrey, J. A. (2012) · Cell Cycle · doi:10.4161/cc.22852 · Cited by 118
MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
Gu, L., Zhu, N., Findley, H. W., & Zhou, M. L. (2008) · Leukemia · doi:10.1038/leu.2008.11 · Cited by 112
Evolution of p53 in hypoxia-stressed Spalax mimics human tumor mutation
Ashur‐Fabian, O., Avivi, A., Trakhtenbrot, L., Adamsky, K., Cohen, M., Kajakaro, G., Joel, A., Amariglio, N., Nevo, E., & Rechavi, G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404998101 · Cited by 113
Conjugation of Cisplatin Analogues and Cyclooxygenase Inhibitors to Overcome Cisplatin Resistance
Neumann, W., Crews, B. C., Sárosi, M. B., Daniel, C. M., Ghebreselasie, K., Scholz, M., Marnett, L. J., & Hey‐Hawkins, E. (2014) · ChemMedChem · doi:10.1002/cmdc.201402353 · Cited by 111
Gene Sets Net Correlations Analysis (GSNCA): a multivariate differential coexpression test for gene sets
Rahmatallah, Y., Emmert-Streib, F., & Glazko, G. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt687 · Cited by 110
The Proline Repeat Domain of p53 Binds Directly to the Transcriptional Coactivator p300 and Allosterically Controls DNA-Dependent Acetylation of p53
Dornan, D., Shimizu, H., Burch, L. R., Smith, A. J., & Hupp, T. R. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8846-8861.2003 · Cited by 108
p53 mutation as a source of aberrant β-catenin accumulation in cancer cells
Cagatay, T., & Ozturk, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205919 · Cited by 110
The C Terminus of p53 Family Proteins Is a Cell Fate Determinant
Harms, K. L., & Chen, X. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.2014-2030.2005 · Cited by 109
Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis
Zheng, T., Wang, J., Zhao, Y., Zhang, C., Lin, M., Wang, X., Yu, H., Liu, L., Feng, Z., & Hu, W. (2013) · Nature Communications · doi:10.1038/ncomms3996 · Cited by 110
Tools for Predicting the Functional Impact of Nonsynonymous Genetic Variation
Tang, H., & Thomas, P. D. (2016) · Genetics · doi:10.1534/genetics.116.190033 · Cited by 114
Spontaneous Feline Mammary Carcinoma Is a Model of HER2 Overexpressing Poor Prognosis Human Breast Cancer
Maria, R. D., Olivero, M., Iussich, S., NAKAICHI, M., Murata, T., BIOLATTI, B., & Renzo, M. F. D. (2005) · Cancer Research · doi:10.1158/0008-5472.907.65.3 · Cited by 108
Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma
Raymond, V. M., Else, T., Everett, J. N., Long, J. M., Gruber, S. B., & Hammer, G. D. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2198 · Cited by 105
Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities
Landré, V., Rotblat, B., Melino, S., Bernassola, F., & Melino, G. (2014) · Oncotarget · doi:10.18632/oncotarget.2431 · Cited by 108
TP53 Mutational signature for aristolochic acid: an environmental carcinogen
Moriya, M., Slade, N., Brdar, B., Medverec, Z., Tomić, K., Jelaković, B., Wu, L., Truong, S., Fernandes, A., & Grollman, A. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26077 · Cited by 106
Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis
Lambert, J. M. R., Moshfegh, A., Hainaut, P. L., Wiman, K. G., & Bykov, V. J. N. (2009) · Oncogene · doi:10.1038/onc.2009.425 · Cited by 111
The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1
Ou, Y.-H., Chung, P.-H., Hsu, F., Sun, T.-P., Chang, W.-Y., & Shieh, S.-Y. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601825 · Cited by 110
TP53 mutations in squamous-cell carcinomas of the conjunctiva: evidence for UV-induced mutagenesis
Ateenyi-Agaba, C. (2004) · Mutagenesis · doi:10.1093/mutage/geh048 · Cited by 106
Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome
Palmero, E. I., Achatz, M. I., Ashton‐Prolla, P., Olivier, M., & Hainaut, P. L. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328333bf00 · Cited by 105
TP53 Mutational Status Is a Potential Marker for Risk Stratification in Wilms Tumour with Diffuse Anaplasia
Maschietto, M. C., Williams, R. D., Chagtai, T., Popov, S. D., Sebire, N. J., Vujanic, G. M., Perlman, E. J., Anderson, J. R., Grundy, P. E., Dome, J. S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109924 · Cited by 106
Genetic alterations and DNA repair in human carcinogenesis
Dixon, K., & Kopras, E. J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.007 · Cited by 109
Asparagine synthetase as a causal, predictive biomarker for l -asparaginase activity in ovarian cancer cells
Lorenzi, P. L., Reinhold, W. C., Rudelius, M., Gunsior, M., Shankavaram, U. T., Bussey, K. J., Scherf, U., Eichler, G. S., Martin, S. E., Chin, K., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0447 · Cited by 105
Alterations of theTP53Gene in Gastric and Esophageal Carcinogenesis
Bellini, M. F., Cadamuro, A. C. T., Succi, M., Proença, M. A., & Silva, A. E. (2012) · BioMed Research International · doi:10.1155/2012/891961 · Cited by 108
Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium
Mai, P. L., Malkin, D. M., Garber, J. E., Schiffman, J. D., Weitzel, J. N., Strong, L. C., Wyss, O., Locke, L., Means, V., Achatz, M. I., et al. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.06.008 · Cited by 104
Molecular basis of inherited diseases: a structural perspective
Steward, R. E., MacArthur, M. W., Laskowski, R. A., & Thornton, J. M. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00195-1 · Cited by 102
Human Papillomavirus Type 16 and TP53 Mutation in Oral Cancer
Dai, M., Clifford, G. M., Calvez‐Kelm, F. L., Castellsagué, X., Snijders, P. J. F., Pawlita, M., Herrero, R., Hainaut, P. L., & Franceschi, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3284 · Cited by 102
Expression of Pirh2, a Newly Identified Ubiquitin Protein Ligase, in Lung Cancer
Duan, W., Gao, L., Druhan, L. J., Zhu, W., Morrison, C., Otterson, G. A., & Villalona-Calero, M. A. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh292 · Cited by 96
MDM2 SNP309 accelerates colorectal tumour formation in women
Bond, G. L., Menin, C., Bertorelle, R., Alhopuro, P., Aaltonen, L. A., & Levine, A. J. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.043539 · Cited by 97
Molecular techniques and genetic alterations in head and neck cancer
Ha, P. K., Chang, S. S., Glazer, C. A., Califano, J. A., & Sidransky, D. (2008) · Oral Oncology · doi:10.1016/j.oraloncology.2008.05.015 · Cited by 96
Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines
Baud, M. G. J., Bauer, M. R., Verduci, L., Dingler, F. A., Patel, K. J., Roy, D. H., Joerger, A. C., & Fersht, A. R. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.035 · Cited by 97
Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene
Liu, Z., Hergenhahn, M., Schmeiser, H. H., Wogan, G. N., Hong, A., & Hollstein, M. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308607101 · Cited by 95

Authors: Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P.
Affiliations: World Health Organization (CH)
German Cancer Research Center (DE)
National Institutes of Health (US)
Corresponding author: Hainaut, Pierre
ORCID: Olivier, Magali
Harris, Curtis C.
Hainaut, Pierre
Venue: Human Mutation
Publisher: Wiley
Published: 2002-05-03
Volume: 19
Issue: 6
Pages: 607-614
ISSN: 1059-7794 (ISSN-L)
1098-1004
DOI: 10.1002/humu.10081
OpenAlex: W2073576377
Cited by: 1,248
References: 14
Citations by year: 2026: 11 · 2025: 20 · 2024: 33 · 2023: 46 · 2022: 33 · 2021: 33 · 2020: 32 · 2019: 31 · 2018: 40 · 2017: 30 · 2016: 37 · 2015: 34 · 2014: 48 · 2013: 43 · 2012: 61
FWCI: 29.66
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4869 d)
Locations: Human Mutation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords: TP53 mutation, somatic mutations, TP53 polymorphisms, mutation patterns, cancer genomics, carcinogen exposure, viral infection, genetic background, database restructuring
MeSH terms: DNA Mutational Analysis, Humans, Mutation, Genes, Tumor Suppressor, Genes, p53, Li-Fraumeni Syndrome, Computational Biology, Internet, Databases, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The IARC TP53 database: New online mutation analysis and recommendations to users

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks